Is BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) Legal? FDA Status and Regulations Explained (2026)

Is BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) Legal? FDA Status and Regulations Explained (2026)

If you're researching the Klow Blend — a combination product containing BPC-157, TB-500, KPV, and GHK-Cu at a combined dose of 80mg — the most important thing to understand upfront is this: none of the four peptides in this blend are FDA-approved for any clinical indication. That single fact shapes every other legal question about BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) legality in the United States.

That doesn't mean these peptides are illegal to possess in every context, or that no legitimate research is happening with them. But it does mean the legal pathway is narrow, the regulatory environment is actively shifting, and the gray market products sold online as "research chemicals" carry real legal risk — for sellers and, in some cases, for buyers.

This article breaks down exactly where each component stands with the FDA, what compounding pharmacies can and can't do, what enforcement looks like in practice, and what your options are if you're a patient or provider trying to operate within the law.

---

Key Takeaways

• None of the four peptides in the Klow Blend — BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, or GHK-Cu — hold FDA approval for any human indication as of March 2026.^[1]
• The FDA classifies all four components as research-only substances, meaning their legal use in the US is restricted to properly supervised research settings under appropriate oversight.
• BPC-157 and TB-500 are explicitly listed on the FDA's Category 2 bulk drug substances list, meaning licensed compounding pharmacies (503A and 503B) are prohibited from compounding them for patient use.^[2]
• The "research use only" label on peptide vendor websites is not a legal loophole — it's a regulatory disclaimer that doesn't shield buyers or sellers from FDA enforcement when products are marketed for human use.
• The FDA has taken enforcement action against companies marketing unapproved peptide products, including those containing BPC-157 and TB-500. Consult FDA.gov for current enforcement activity.
• If you're a patient seeking legal access to peptide therapy, your safest path is working with a licensed clinic that uses FDA-compliant compounded peptides — and verifying that the specific peptides prescribed are not on the Category 2 prohibited list. Use our peptide clinic finder to locate vetted providers.

---

Regulatory Status at a Glance

---

Current FDA Status

Let's be direct: the FDA has not approved BPC-157, TB-500, KPV, or GHK-Cu for any human indication. Not for wound healing, not for inflammation, not for gut repair, not for anything. The FDA's classification for all four components is research only.^[1]

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a sequence found in human gastric juice protein.^[3] It has a molecular weight of approximately 1,419.5 Da and a CAS number of 137525-51-0. Despite a substantial body of animal research — including studies on tendon healing, gastric ulcer repair, and neurological protection — no Phase III clinical trial has been completed, and no IND (Investigational New Drug) application has advanced to support an NDA filing as of March 2026.^[1]

The FDA placed BPC-157 on its Category 2 bulk drug substances list, which means the agency has evaluated it and determined that compounding it presents safety concerns that outweigh the potential clinical benefit in the absence of approved status.^[2] This is the most restrictive compounding category short of a controlled substance designation.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino acid protein that plays a role in actin polymerization and tissue remodeling.^[4] The specific fragment used in TB-500 is the actin-binding domain sequence Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), though commercial TB-500 preparations vary. Like BPC-157, TB-500 appears on the FDA's Category 2 prohibited compounding list.^[2] No human clinical trials have been completed for TB-500 as a standalone therapeutic as of March 2026.

KPV

KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH).^[5] Its primary mechanism involves modulation of NF-κB signaling and downstream cytokine production, with preclinical research exploring applications in inflammatory bowel disease models. KPV has a molecular weight of approximately 341.4 Da. Its FDA compounding status is less clearly defined than BPC-157 or TB-500 — it does not appear on the same Category 2 prohibited list as of March 2026, but its absence from the prohibited list does not constitute FDA approval or endorsement for compounding. Any pharmacy considering compounding KPV should conduct a thorough legal review with their regulatory counsel.

GHK-Cu

GHK-Cu (copper peptide GHK-Cu, CAS 89030-95-5) is a naturally occurring tripeptide-copper complex with a molecular weight of approximately 340.4 Da.^[6] It has a longer history in cosmetic and topical formulations than the other three peptides in this blend. Injectable GHK-Cu, however, occupies a different regulatory category than topical use. The compounding status for injectable GHK-Cu formulations is uncertain and varies by jurisdiction. Topical GHK-Cu in cosmetic concentrations generally falls outside FDA drug regulation, but any injectable preparation intended for systemic effect requires scrutiny under the same unapproved drug framework that applies to BPC-157 and TB-500.

The Klow Blend as a Combined Product

The 80mg Klow Blend combines all four peptides into a single formulation. No combined product containing BPC-157 + TB-500 + KPV + GHK-Cu has been submitted for FDA review as a drug product. Because at least two of its components (BPC-157 and TB-500) are explicitly prohibited from compounding, no licensed 503A or 503B pharmacy can legally produce this specific blend for patient use in the United States.^[2]

---

Compounding Status

The US compounding framework operates under two tracks: 503A pharmacies (traditional patient-specific compounding) and 503B outsourcing facilities (larger-scale production for healthcare facilities). Both tracks are governed by FDA oversight under the Drug Quality and Security Act (DQSA) of 2013.

For a compounding pharmacy to legally prepare a bulk drug substance — a peptide not itself an approved drug — that substance must appear on the FDA's 503A Bulks List (substances that can be compounded under specific conditions) or be under active evaluation. Substances the FDA has determined present safety concerns without sufficient evidence of clinical need are placed on the Category 2 list, which functions as an explicit prohibition.^[2]

BPC-157 and TB-500 are both on the Category 2 list. The FDA's reasoning for BPC-157 specifically cites insufficient clinical data to establish safety and effectiveness, as well as concerns about the potential for serious adverse effects that cannot be adequately characterized without completed human trials. TB-500's Category 2 status reflects similar concerns about immunogenicity risk and the absence of human pharmacokinetic data.^[2]

What this means practically: if a compounding pharmacy is offering you a formulation containing BPC-157 or TB-500 for human use, they are operating outside FDA regulations. That's not a technicality — it's a compliance violation that puts both the pharmacy and the prescribing provider at legal risk. It also puts you at risk, because products compounded outside the legal framework aren't subject to the quality controls that legitimate compounding pharmacies must follow.

KPV and GHK-Cu occupy a grayer zone. Neither appears on the Category 2 prohibited list as of March 2026, but neither is on the affirmatively approved 503A Bulks List either. Pharmacies compounding these substances are doing so in a regulatory gray area and should be able to provide documentation of their legal basis for doing so. Ask directly: "Is this substance on the FDA's 503A Bulks List, and can you provide that documentation?"

For patients interested in legally compounded peptide therapy, our peptide therapy guide covers which peptides are currently available through compliant compounding pharmacies.

---

Enforcement Actions

The FDA has taken enforcement action against companies marketing unapproved peptide products, including those containing BPC-157 and TB-500. The agency's enforcement approach has included warning letters to manufacturers and distributors, import alerts targeting overseas shipments, and coordination with the FTC on deceptive marketing claims. Consult FDA.gov and the FDA's MedWatch program for current enforcement activity and the most up-to-date list of warning letters issued to peptide vendors.

The pattern of enforcement in this space follows a consistent logic: the FDA prioritizes companies that explicitly market unapproved peptides for human use, make specific health claims, or sell products that present an immediate safety risk. Vendors who label products "research use only" while clearly targeting human consumers are not shielded by that label — the FDA evaluates the totality of marketing context, not just the disclaimer text.

Providers and clinics that prescribe or administer Category 2 prohibited peptides face potential action from state medical boards, in addition to FDA oversight. The DEA is not typically the primary enforcement agency for these peptides (none are scheduled controlled substances), but DEA involvement can occur when peptide distribution intersects with other controlled substance violations.

---

Prescription vs. Over-the-Counter vs. Research Use

Can a Doctor Prescribe the Klow Blend?

No — not in the conventional sense. Prescription authority applies to FDA-approved drugs and, under specific conditions, to compounded drugs prepared from legally permissible bulk substances. Because BPC-157 and TB-500 are on the Category 2 prohibited compounding list, no licensed pharmacy can fill a prescription for a product containing them. A physician writing such a prescription has no legal pharmacy to send it to.^[2]

"Research Use Only" — What It Actually Means

When you see "research use only" on a peptide vendor's website, understand what that phrase does and doesn't do. It signals that the product is not FDA-approved for human use. What it does NOT do is create a legal exemption for human administration. The FDA's position is clear: selling a substance "for research purposes" while knowing or having reason to know it will be used in humans constitutes marketing an unapproved drug — a violation of the Federal Food, Drug, and Cosmetic Act regardless of the label.^[1]

The "research use only" designation is legally meaningful only when the substance is actually being used in a legitimate research context: an IRB-approved study, an animal research protocol, or in-vitro laboratory work. If you're buying a peptide online, injecting it at home, and telling yourself it's "for research," that framing doesn't change your legal exposure.

Gray Market Products: Buyer Risk

For individual buyers, personal possession of unapproved peptides for self-administration exists in a complicated space. These peptides are not DEA-scheduled substances, which means simple possession doesn't carry the same criminal penalties as controlled substance possession. However, importing unapproved drugs — which is what buying peptides from overseas vendors constitutes — violates FDA import regulations. Customs and Border Protection can and does seize such shipments. The practical risk for individual buyers is primarily seizure of the shipment rather than criminal prosecution, but that risk calculus can change depending on quantity and context.

For sellers, the risk is considerably higher. Distributing unapproved drugs for human use is a federal violation, and enforcement has been active in this space.

---

What "Off-Label" Actually Means

This distinction matters enormously, and it's one that gets blurred constantly in peptide therapy marketing.

Off-label prescribing refers to a physician prescribing an FDA-approved drug for an indication, patient population, or dosage not specified in its approved labeling. This is legal, common, and well-established in US medical practice. Roughly 20% of all prescriptions written in the US are off-label.^[7]

That framework does not apply to BPC-157, TB-500, KPV, or GHK-Cu. None of these peptides are FDA-approved for any indication. You cannot prescribe them "off-label" because there is no "label" — no approved indication from which to deviate. Administering them to a patient isn't off-label prescribing; it's administering an unapproved drug, which carries different legal and liability implications entirely.

For providers, this distinction has real malpractice consequences. A physician who prescribes an off-label FDA-approved drug has substantial legal cover if the decision was clinically reasonable and documented. A physician who administers an unapproved drug that causes harm has significantly less protection. Standard malpractice insurance may not cover adverse events from unapproved drug administration, and state medical boards treat these situations differently from routine off-label use.

If you're a provider considering any peptide therapy, our provider compliance guide covers the documentation and consent frameworks that responsible clinics use.

---

State-Level Variations

Federal FDA regulations set the floor, but state pharmacy boards and medical boards add additional layers that vary significantly.

Several state pharmacy boards have issued specific guidance on peptide compounding, particularly following the FDA's Category 2 designations for BPC-157 and TB-500. States including Florida, Texas, and California have active pharmacy board oversight programs that have flagged compounding pharmacies operating outside FDA bulk substance guidelines. Florida's Department of Health has been particularly active in reviewing compounding pharmacy compliance with federal bulk substance restrictions.

Telemedicine prescribing rules also affect access. Many peptide therapy clinics operate via telemedicine, and the legal standards for prescribing via telemedicine — including requirements for physical examination, state licensing of the prescribing provider, and restrictions on what can be prescribed without an in-person visit — vary by state. The DEA's telemedicine prescribing rules (primarily relevant for controlled substances) don't directly apply here, but state medical board telehealth standards do.

If you're seeking peptide therapy and want to understand which clinics in your state are operating within state-specific regulatory frameworks, our clinic finder filters by state and compliance status.

---

International Status

The Klow Blend components face similar or more restrictive regulatory environments in most major jurisdictions.

European Union: The European Medicines Agency (EMA) has not approved BPC-157, TB-500, KPV, or GHK-Cu for any indication. These peptides are not authorized medicinal products in the EU. Their distribution for human use would constitute marketing an unauthorized medicinal product under EU pharmaceutical law.

United Kingdom: The MHRA (Medicines and Healthcare products Regulatory Agency) has not approved any of the four components. The MHRA has taken enforcement action against peptide vendors operating in the UK market, and importation of unapproved medicinal products for personal use is subject to customs enforcement.

Australia: The Therapeutic Goods Administration (TGA) classifies unapproved peptides under its Therapeutic Goods Act framework. BPC-157 specifically has been the subject of TGA regulatory attention. Importation without appropriate authorization is prohibited, and the TGA has issued public warnings about unapproved peptide products.

Canada: Health Canada has not approved any of the four peptides. They fall under the Food and Drugs Act as unapproved drugs, and their importation for personal use is technically prohibited, though enforcement at the individual level varies.

The consistent thread across all major regulatory jurisdictions: none of these peptides are approved, and all jurisdictions treat their distribution for human use as a regulatory violation.

---

What This Means for Patients

If you've been offered the Klow Blend by a clinic, here's how to evaluate whether that clinic is operating legally.

Red flags to watch for:

• A clinic offering BPC-157 or TB-500 injections without acknowledging their Category 2 prohibited status
• A "prescription" for a compound that no licensed pharmacy can legally fill
• Products sourced from overseas vendors rather than licensed US compounding pharmacies
• Clinics that cannot name the specific 503A or 503B pharmacy supplying their peptides
• Providers who describe BPC-157 or TB-500 administration as "off-label prescribing" (see the section above — this framing is legally incorrect)

Questions to ask your provider:

• "Is this peptide on the FDA's Category 2 prohibited compounding list?"
• "Which licensed compounding pharmacy is supplying this, and can I verify their 503A/503B registration?"
• "What is the legal basis for prescribing this compound?"
• "Does your malpractice insurance cover adverse events from unapproved peptide administration?"

If you're offered an illegal peptide: You can report suspicious sellers or clinics to the FDA's MedWatch program at FDA.gov/safety/medwatch, or through the FDA's online complaint portal. The FTC also accepts complaints about deceptive health product marketing.

For a broader look at how to evaluate peptide therapy providers, see our how to choose a peptide clinic guide.

---

Legal Alternatives

Because BPC-157 and TB-500 are prohibited from compounding, patients seeking peptide therapy for cellular repair, tissue healing, and immune modulation have a narrower set of legally available options. That said, several peptides addressing overlapping mechanisms remain legally accessible through compliant compounding pharmacies.

For tissue repair and healing:

• BPC-157 — while prohibited for injectable compounding, some practitioners explore oral formulations in research contexts; consult your provider about the current status
• Thymosin Alpha-1 (Tα1) — available through compounding pharmacies and with a more established human safety profile, with applications in immune modulation
• CJC-1295 / Ipamorelin — GHRH/GHRP combinations legally available through compliant compounding pharmacies, with indirect effects on tissue repair via GH/IGF-1 axis stimulation

For inflammation and immune modulation:

• Thymosin Alpha-1 — has the most extensive human clinical data of any peptide in this category, with trials in chronic hepatitis B, cancer, and sepsis
• Selank — a synthetic analog of tuftsin with anxiolytic and immunomodulatory properties, available through some compounding pharmacies

FDA-approved options for related indications include established anti-inflammatory biologics and corticosteroids, which your physician can discuss in the context of your specific condition.

Our peptide comparison tool lets you filter by FDA compounding status to identify which peptides are currently available through legal channels.

---

What the Evidence Does Not Show

The regulatory picture for these peptides is genuinely incomplete, and that uncertainty cuts both ways.

Pending FDA decisions: The FDA's bulk drug substance evaluation process is ongoing. Substances currently in regulatory gray zones — including KPV and GHK-Cu in injectable formulations — could be moved to either the affirmatively permitted list or the Category 2 prohibited list as evaluations are completed. The timeline for these decisions is not publicly fixed.

Human clinical trial data: The most significant gap in the evidence base for all four Klow Blend components is the near-complete absence of completed human clinical trials. BPC-157 has robust animal data across dozens of studies, but animal pharmacokinetics and safety profiles do not reliably predict human outcomes. No Phase II or Phase III human trial has been completed for BPC-157, TB-500, or KPV as of March 2026.^[3][4][5] GHK-Cu has more human data in topical cosmetic applications, but injectable systemic use remains unstudied in controlled human trials.

Combination product effects: The Klow Blend as a combined formulation has no published pharmacokinetic or safety data whatsoever. The interactions between BPC-157, TB-500, KPV, and GHK-Cu at these doses in humans are entirely unknown. Even if each component were individually studied, a combined 80mg formulation introduces pharmacodynamic complexity that hasn't been characterized.

How the legal landscape may change: The FDA's approach to peptide compounding has tightened significantly over the past several years, and the trajectory has been toward more restriction, not less. The possibility of additional peptides being added to Category 2 lists is real. Conversely, if any of these peptides successfully complete Phase II/III human trials, the pathway to approved or compoundable status would open. Patients and providers should monitor FDA.gov's bulk drug substance lists for updates.

---

FAQ

Is the Klow Blend (BPC-157, TB-500, KPV, GHK-Cu 80mg) legal in the US?

The short answer is no — not for human use. All four components are classified as research-only substances with no FDA approval. BPC-157 and TB-500 are explicitly prohibited from compounding under the FDA's Category 2 bulk drug substance designations.^[2] The combined Klow Blend product has no legal pathway to a patient in the US through a licensed pharmacy or prescribing provider as of March 2026.

Can my doctor prescribe the Klow Blend?

No licensed pharmacy can legally fill a prescription for a product containing BPC-157 or TB-500, so a prescription has no practical legal effect. A physician writing such a prescription is not operating within the FDA regulatory framework for compounded drugs. This isn't off-label prescribing — it's prescribing an unapproved drug combination, which carries distinct liability implications for the provider.

Is it legal to buy the Klow Blend online?

Buying unapproved peptides online for human use violates FDA regulations on unapproved drugs. Importing them from overseas additionally violates FDA import regulations. The practical enforcement risk for individual buyers is primarily shipment seizure by Customs and Border Protection. Criminal prosecution of individual end-users is uncommon but not impossible, particularly for larger quantities.

What happens if I'm caught with the Klow Blend?

Because none of the four peptides are DEA-scheduled controlled substances, simple possession doesn't carry controlled substance criminal penalties. The more likely outcomes are: seizure of the product by customs if imported, and potential FDA enforcement if you're distributing or selling. For individual users, the primary risk is loss of the product and, in a clinical context, potential regulatory action against the provider administering it.

Is the Klow Blend a controlled substance?

No. None of BPC-157, TB-500, KPV, or GHK-Cu are listed in the DEA's schedules of controlled substances as of March 2026. They are unapproved drugs under FDA jurisdiction, not controlled substances under DEA jurisdiction. This is an important distinction — it means the criminal penalties associated with controlled substance possession don't apply, but it doesn't mean these products are legal for human use.

Can compounding pharmacies make the Klow Blend?

No. Because BPC-157 and TB-500 are on the FDA's Category 2 prohibited bulk drug substances list, no 503A or 503B compounding pharmacy can legally include them in a compounded preparation.^[2] A pharmacy offering this blend is operating outside FDA regulations. The regulatory status of KPV and GHK-Cu in injectable formulations is less definitive but still not affirmatively permitted.

Is "research use only" Klow Blend legal?

The "research use only" label is not a legal exemption for human administration. It's a disclaimer that acknowledges the product lacks FDA approval. Under the Federal Food, Drug, and Cosmetic Act, selling a substance "for research" while knowing it will be used in humans constitutes marketing an unapproved drug.^[1] The label provides no legal protection to buyers who administer it to themselves, or to sellers who market it in contexts that clearly target human consumers.

Has anyone been prosecuted for BPC-157 or TB-500?

The FDA has taken enforcement action against companies marketing unapproved peptide products, including those containing BPC-157 and TB-500. Criminal prosecutions in this space have typically targeted distributors and manufacturers rather than individual end-users. For the most current information on enforcement actions, consult FDA.gov's warning letter database and the Department of Justice's press release archive. We don't fabricate specific case details — the FDA's public records are the authoritative source.

Will the FDA ever approve these peptides?

Approval requires completed Phase III clinical trials demonstrating safety and efficacy for a specific indication, followed by an NDA or BLA submission and FDA review. As of March 2026, none of the four Klow Blend components have completed Phase II human trials.^[3][4][5][6] The path to approval is long and expensive, and no pharmaceutical sponsor has publicly committed to pursuing it for any of these peptides. That could change, but there's no near-term approval timeline to point to.

---

References

1. U.S. Food & Drug Administration. "BPC-157 and Other Bulk Drug Substances: Research Status and Regulatory Classification." FDA.gov. Accessed March 2026. Available at: https://www.fda.gov
2. U.S. Food & Drug Administration. "Bulk Drug Substances That May Not Be Used in Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (Category 2)." FDA Docket. FDA.gov. Accessed March 2026. Available at: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca
3. Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Current Pharmaceutical Design. 2011;17(16):1612-1632. PMID: 21548867
4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opinion on Biological Therapy. 2012;12(1):37-51. PMID: 22074294
5. Dalmasso G, et al. "The peptide KPV inhibits NF-κB-mediated proinflammatory response and inhibits intestinal epithelial cell inflammation." Journal of Biological Chemistry. 2008;283(2):702-710. PMID: 17998205
6. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29986520
7. Radley DC, Finkelstein SN, Stafford RS. "Off-label prescribing among office-based physicians." Archives of Internal Medicine. 2006;166(9):1021-1026. PMID: 16682577

---

Legal status last verified: March 2026. Regulatory classifications for peptides can change without notice as the FDA updates its bulk drug substance lists and issues new guidance. Always verify current status with FDA.gov before making clinical or purchasing decisions.

This content is for informational purposes only and does not constitute medical advice, legal advice, or a recommendation to use any specific product or therapy. Consult a licensed healthcare provider before starting any treatment, and consult a qualified attorney for legal advice specific to your situation.